China Meheco Group's (SHA:600056) unit, Tianfang Pharmaceutical, received approval from the Chinese drug administrator for its drug supplementary application for lincomycin hydrochloride injection after the drug passed regulatory evaluation, according to a Shanghai bourse filing on Wednesday.
The drug, which is mainly used for the treatment of severe infections caused by susceptible strains such as streptococci, pneumococci, and staphylococci, was tested for its consistency in quality and efficiency.
The Chinese drugmaker's shares dropped less than 2% during the afternoon trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments